Pharmaust Limited (AU:PAA) has released an update.
PharmAust Limited, a clinical-stage biotechnology company, has announced the strategic appointment of Dr. Katie MacFarlane, a seasoned pharmaceutical executive with over three decades of industry experience, to its Board of Directors. Dr. MacFarlane brings a wealth of expertise in drug development and commercialization, aimed at bolstering PharmAust’s position as a leader in neurodegenerative diseases. This move is poised to enhance the company’s visibility in the U.S. market and contribute to the advancement of their promising ALS treatment.
For further insights into AU:PAA stock, check out TipRanks’ Stock Analysis page.
